WorldCat Identities

Molina, Jean-Michel

Overview
Works: 30 works in 33 publications in 2 languages and 46 library holdings
Roles: Thesis advisor, Author, Contributor, Other, Opponent, Photographer
Publication Timeline
.
Most widely held works by Jean-Michel Molina
Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals by Valérie Martinez( )

2 editions published in 2012 in English and held by 4 WorldCat member libraries worldwide

Microsporidioses humaines : aspects moléculaires de l'excrétion et de la viabilité parasitaires -applications pharmacologiques by Jean Menotti( Book )

2 editions published in 2004 in French and held by 3 WorldCat member libraries worldwide

Multimodal techniques failed to detect cytomegalovirus in human glioblastoma samples by Marie-Pierre Loit( )

1 edition published in 2018 in English and held by 2 WorldCat member libraries worldwide

Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial by EASIER ANRS 138 study group( )

1 edition published in 2016 in English and held by 2 WorldCat member libraries worldwide

Etude de la prévalence, de l'incidence, des facteurs de risque et de la réponse au traitement des infections sexuellement transmissibles dans une population à haut risque d'hommes ayant des relations sexuelles avec des hommes : les patients de l'étude IPERGAY : étude by Martin Siguier( Book )

1 edition published in 2014 in French and held by 2 WorldCat member libraries worldwide

Actuellement, la prévalence des Infections Sexuellement Transmissibles (IST) augmente en France, comme dans de nombreux pays d'Europe, notamment chez les Hommes ayant des rapports Sexuels avec des Hommes (HSH). Lancé en mars 2012, l'essai IPERGAY évalue l'efficacité d'un traitement antirétroviral en prophylaxie préexposition de l'infection par le VIH chez les HSH à haut risque d'IST. Il a aussi pour objectif d'évaluer l'incidence des autres IST. Cette étude prospective et multicentrique concerne 160 participants du protocole IPERGAY, chez lesquels nous avons étudié toutes les IST survenues durant leur suivi.Dans notre étude, l'incidence globale des IST est de 35.9 participants pour 100 personnes-années, et les incidences pour chaque IST sont de : 23.7 pour N. gonorrhoeae, 17.2 pour C. trachomatis, 7.9 pour la syphilis, 4.3 pour le VIH. Il n'y a pas eu d'infections par les Virus des Hépatites A et B durant l'essai.Les facteurs augmentant le risque d'acquisition d'une IST identifiés dans notre étude sont : la pratique de rapports anaux réceptifs non protégés au cours des 6 derniers mois avant la survenue d'une IST ; la rencontre régulière de partenaires en sex-parties. Les facteurs protecteurs sont : la tranche d'âge 27-46 ans, en comparaison avec la tranche d'âge 18-26 ans ; les rencontres de partenaires sur internet.Les incidences des IST sont très élevées dans la population de notre étude. Il est donc important d'intensifier le dépistage et le traitement des IST chez les HSH, par l'édition de recommandations spécifiques. Le modèle de suivi et de counselling appliqué au sein de l'essai IPERGAY pourrait être, à ce titre, l'un des schémas recommandés
Traitement et prévention de la transmission de l'infection à VIH : analyse pharmacocinétique de l'emtricitabine par approche de population by Elodie Valade( )

1 edition published in 2015 in French and held by 2 WorldCat member libraries worldwide

Emtricitabine is a key antiretroviral drug in the strategy to fight against HIV infection. Indeed, emtricitabine is recommended in first-line treatment for HIV infection in adults, as well as for the prevention of HIV transmission. Although emtricitabine is a key molecule, it remains poorly studied until now. It is therefore essential to analyze and characterize the pharmacokinetics of emtricitabine in the different populations that may be exposed to this drug. A population approach was used to perform pharmacokinetic analyses, allowing us to describe the pharmacokinetics with few samples per individual (ethical constraints, difficulty of samples collection...) and allowing us to explain the observed variability. The study reporting emtricitabine pharmacokinetics in adults highlighted a change in emtricitabine kinetic profile depending on the state of renal function. The developed model allowed us to evaluate the current dosing recommendations. To optimize efficiency, simulations of alternative regimens in patients with moderate renal impairment were performed. As part of the prevention of mother to child transmission, the study describing emtricitabine pharmacokinetics in pregnant women showed a change in pharmacokinetics during the gestational period. However, it did not seem necessary to adjust the dosage during pregnancy. The latest work focused on emtricitabine pharmacokinetics in the male genital tract. Studying the penetration in the genital tract is of major interest for treatment but also for prevention of HIV transmission in the context of pre-exposure prophylaxis. Our study reported a significant distribution of emtricitabine in the genital compartment, with concentrations in seminal plasma higher than concentrations in blood plasma
EPIDEMIOLOGIE DES DIARRHEES A CLOSTRIDIUM DIFFICILE AU COURS DE L'INFECTION PAR LE V.I.H. : UNE ETUDE CAS-TEMOIN DANS UNE UNITE SPECIALISEE by Yvan Hutin( Book )

1 edition published in 1992 in French and held by 2 WorldCat member libraries worldwide

ROLE DU VIRUS DE L'IMMUNODEFICIENCE HUMAINE SUR LA PRODUCTION DE CYTOKINES PAR LES CELLULES DE LA LIGNEE MONOCYTAIRE by JEAN-MICHEL MOLINA( Book )

2 editions published in 1991 in French and held by 2 WorldCat member libraries worldwide

NOUS AVONS ETUDIE LE ROLE DU VIH, SUR LA PRODUCTION, PAR LES CELLULES MONOCYTAIRES, DE TNF, D'IL-1; D'IL-6, ET DE GM-CSF. TROIS MODELES DIFFERENTS ONT ETE UTILISES: LA LIGNEE THP-1, DES CELLULES MONONUCLEES (PBMC) ET DES MACROPHAGES. CES CELLULES ONT ETE INFECTEES OU EXPOSEES A PLUSIEURS SOUCHES DE VIH, AINSI QU'A LA GLYCOPROTEINE GP 120(RGP 120). NOUS N'AVONS DETECTE AUCUNE PRODUCTION DE PROTEINE OU D'ARN MESSAGER POUR CES CYTOKINES, DANS LES CULTURES DE CELLULES INFECTEES OU STIMULEES PAR LE VIH, OU LA RGP 120. APRES STIMULATION PAR L'ENDOTOXINE, LES CELLULES INFECTEES PAR LA VIH, RESTENT CEPENDANT CAPABLES DE PRODUIRE DE L'ARN MESSAGER OU DES PROTEINES POUR CES DIFFERENTES CYTOKINES, EN QUANTITES COMPARABLES A CELLES DES CELLULES NON INFECTEES. LES CELLULES THP-1, A LA PHASE AIGUE DE L'INFECTION, SONT EN REVANCHE CAPABLES DE PRODUIRE, APRES STIMULATION DES QUANTITES TRES IMPORTANTES DE TNF ET D'IL-1B. CETTE PRODUCTION POURRAIT ETRE LIEE A UN STADE DE DIFFERENCIATION PLUS AVANCE, INDUIT PAR L'INFECTION VIRALE. NOUS AVONS EGALEMENT OBSERVE QUE LA STIMULATION PAR L'ENDOTOXINE, DES CELLULES THP-1 INFECTEES PAR LE VIH, ENTRAINAIT UNE AUGMENTATION DOSE-DEPENDANTE DE LA REPLICATION VIRALE, EN PARTIE LIEE A LA LIBERATION DE TNF PAR CES CELLULES
Once-Daily Administration of Antiretrovirals Pharmacokinetics of Emerging Therapies by Anne-Marie Taburet( )

1 edition published in 2003 in English and held by 2 WorldCat member libraries worldwide

LES INFECTIONS A STREPTOCOQUES MILLERI : ETUDE CLINIQUE, BACTERIOLOGIQUE ET THERAPEUTIQUE DE 43 OBSERVATIONS by JEAN-MICHEL MOLINA( Book )

1 edition published in 1987 in French and held by 2 WorldCat member libraries worldwide

Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe? by Jean-Michel Molina( )

1 edition published in 2013 in English and held by 2 WorldCat member libraries worldwide

Risk factors for invasive pneumococcal disease in HIV-infected adults in France in the highly active antiretroviral therapy era( )

1 edition published in 2014 in English and held by 1 WorldCat member library worldwide

Invasive pneumococcal diseases remain frequent and severe in HIV-infected subjects. To identify opportunities for prevention, we assessed risk factors of invasive pneumococcal diseases (IPD) in HIV-infected patients over a 10-year period in France. We performed a retrospective case-control study in a reference centre of HIV management in Paris. All HIV-infected patients having suffered from IPD between 2000 and 2011 were included. Control subjects were HIV-infected with no history of IPD or pneumonia, matched by date of diagnosis of HIV with controls. Two controls were randomly selected for each subject. In all, 42 HIV-infected patients presented 44 IPD episodes during the study period and were compared to 84 controls. In the multivariate analysis, patients with IPD were more likely than controls to have a Charlson Comorbidity Index e" (adjusted OR = 7.07, 95% CI 1.99-25.1, p = 0.003), CD4-cell count <200/cells/æL (aOR = 6.93, 95% CI 1.80-26.7, p = 0.005), HIV-RNA viral load>400 copies/mL (aOR = 5.56, 95% CI 1.58-19.5, p = 0.007) and a non-European origin (aOR = 4.26, 95% CI 1.02-17.9, p = 0.047). HIV-infected patients with a higher burden of comorbidities, uncontrolled HIV replication, low CD4-cell counts and/or of non-European origin are at higher risk of developing IPD. Better screening for and management of HIV infection is necessary to reduce the risk of IPD
Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

Programmation novembre-décembre 2010. Opéra de Massy affiche by Jean-Michel Molina( Visual )

1 edition published in 2010 in French and held by 1 WorldCat member library worldwide

Costs and benefits of on-demand HIV preexposure prophylaxis in MSM( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

Abstract : Objectives: We undertook the economic evaluation of the double-blind randomized ANRS-IPERGAY trial, which showed the efficacy of on-demand preexposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF)-emtricitabine (FTC) in preventing HIV infection among high-risk MSM. Design and methods: The economic evaluation was prospective. Counseling, drugs (TDF-FTC at [Euro sign]500.88 for 30 tablets), tests, visits, and hospital admissions were valued based on in-trial use. The cost of on-demand PrEP/HIV infection averted was compared with the yearly and lifetime costs of HIV infection in France in a cost and benefits analysis. Results: The yearly number of participants needed to treat to prevent one HIV infection was 17.6 (95% confidence interval = 10.7-49.9). The annual cost of counseling was [Euro sign]690/participant. The total 1-year costs of PrEP were [Euro sign]4271/participant, of which [Euro sign]3129 (73%) were drug costs corresponding to 15 tablets of TDF-FTC/month. The yearly cost of on-demand PrEP to avoid one infection was [Euro sign]75 258. Using TDF-FTC generic ([Euro sign]179.9/30 tablets) reduced the 1-year costs of on-demand PrEP to [Euro sign]2271/participant and [Euro sign]39 970/infection averted, respectively. Using TDF-FTC at international market discounted prices ([Euro sign]60/30 tablets) reduced the costs to [Euro sign]1517/participant and the cost to [Euro sign]26 787/infection averted, comparable with the yearly treatment cost of HIV infection in France. On-demand PrEP was found to be cost saving in France if the duration of exposure was less than 7.5 years at current drug price and 13 years at generic price. Conclusion: On-demand PrEP in high-risk MSM with TDF-FTC can be considered cost saving. Other benefits include the treatments of other diseases and reductions in secondary infections
Tenofovir disoproxil fumarate-induced Fanconi's syndrome during HIV postexposure prophylaxis( )

1 edition published in 2016 in English and held by 1 WorldCat member library worldwide

 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.95 (from 0.88 for Hepatic st ... to 0.98 for Programmat ...)

Languages
English (14)

French (9)